LYNPARZA (olaparib) get three new approvals in Japan
Approvals in three types of cancer are based on the PAOLA-1, PROfound and POLO Phase 3 Trials
AstraZeneca and Merck, known as MSD outside the US and Canada announced that LYNPARZA has been approved in Japan for the treatment of three types of advanced cancer: ovarian, prostate and pancreatic cancer. The three approvals authorise LYNPARZA for use as maintenance